-- New Panther Fusion® Module
Expands Molecular Testing Capabilities, Increases Productivity and
Flexibility for the Laboratory
MARLBOROUGH, Massachusetts,
June 29, 2017 /PRNewswire/
-- Hologic, Inc. (Nasdaq: HOLX) has obtained a CE mark in
Europe for its new Panther Fusion
system and Panther Fusion assays for flu and respiratory testing,
the Company announced today. The Fusion module system offers
laboratories the ability to extend the testing capabilities of the
existing Panther system.
The Panther Fusion module is an in-lab upgrade to the
Panther® instrument. This addition adds the
flexibility of PCR (polymerase chain reaction) to the proven
performance of TMA (transcription-mediated amplification), which is
used by the Panther system. Offering labs multiple
chemistries on a single platform enables further consolidation of
their lab testing portfolio. The Panther Fusion system retains all
the key benefits of the Panther platform, including fully automated
sample-to-result automation, multiple tests from a single sample,
random access sample processing, continuous loading, and STAT
capabilities.
Additional benefits include a higher throughput of up to 335
Panther Fusion tests in eight hours, or up to 500 Fusion and
Aptima® tests. Flexibility is also improved
with the addition of Open Access functionality to run
laboratory-developed tests and protocols. This new capability
allows laboratories to concentrate on developing assays, while the
Panther Fusion system automates workflow and reduces overall
hands-on-time.
"The Panther Fusion system, the latest innovation from our
Diagnostics division, creates an integrated workflow that provides
our customers with enhanced flexibility and increased efficiency,"
said João Malagueira, VP Sales Diagnostics, EMEA. "The addition of
the flu and respiratory assays to the broad menu of Aptima tests
already available for the Panther instrument further extends the
range of diagnostics tests that laboratories can run on one Hologic
system. Hologic's flu and respiratory assays enable customers to
run only the targets requested for a patient, allowing for
personalized testing and helping them control costs within their
laboratories."
The Panther Fusion respiratory panel assays include the Panther
Fusion Flu A/B/RSV, Panther Fusion Paraflu, and Panther Fusion
AdV/hMPV/RV tests. The Panther Fusion respiratory assays
offer a modular approach to syndromic testing via the ability to
run one, two or all three assays from a single patient specimen
depending on the needs of a given patient.
The new Panther Fusion PCR assays, combined with the Aptima TMA
assays, make the Panther Fusion system the only instrument
worldwide that combines TMA, real-time TMA and real-time PCR with
full sample to result automation.
The Panther Fusion system and Panther Fusion assays have not
been cleared for marketing by the U.S. Food and Drug
Administration, and are not available for diagnostic use in
the United States.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company
primarily focused on improving women's health and well-being
through early detection and treatment. For more information
on Hologic, visit www.hologic.com.
Hologic, The Science of Sure, Aptima and Panther are registered
trademarks of Hologic, Inc. in the United
States and/or other countries.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
This information is not intended as a product solicitation or
promotion where such activities are prohibited. For specific
information on what products are available for sale in a particular
country, please contact a local Hologic sales representative or
write to womenshealth@hologic.com.
Hologic Media Contact:
Jane
Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Hologic Investor Contact:
Michael Watts
Vice President, Investor Relations and Corporate Communications
(858) 410-8588
michael.watts@hologic.com
Photo -
https://mma.prnewswire.com/media/528507/Hologic_Inc_Panther_Fusion.jpg